Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 774 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05555888RecruitingPhase 2
Immunotherapy plus short-course radiation for early rectal cancer
This study tests whether combining immunotherapy with a short course of radiation given before surgery can improve outcomes in early-stage rectal cancer. It may help the immune system work better against the tumor before it is removed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06421415Recruiting
Long-term effects of allergy shots in children
This study looks at how well allergy shots or drops work over the long term in children who received this treatment at Odense University Hospital. It aims to understand if the benefits last for years after treatment ends.
Odense, Odense CAges 4–18 - NCT04992780RecruitingPhase 2
Hypo-fractionated radiation versus standard radiation for lung cancer
This study compares two different radiation schedules for stage III non-small cell lung cancer, both combined with chemotherapy and immunotherapy. It aims to see whether giving radiation in a different way can work as well (or better) and be safe while treating the cancer.
Kansas City, KansasAges 18 years+ - NCT04886401Recruiting
Study predicting response to pembrolizumab in advanced lung cancer
This study looks back at prior treatment to learn which patients with advanced non-small cell lung cancer (NSCLC) are more likely to respond to pembrolizumab, an immune therapy given up front. The results may help doctors better predict who benefits from this treatment.
BrestAges Any age - NCT05098197RecruitingEarly Phase 1
Study of TIL cell therapy for advanced liver, bile, or pancreas cancer
This trial studies a treatment called TIL therapy, which uses your own immune cells grown from a tumor sample, to treat advanced cancers of the liver/bile ducts or pancreas. It’s mainly for people whose standard treatments have already failed (or none exist), and who can safely provide tumor tissue for the cell preparation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05098184RecruitingEarly Phase 1
Study TIL treatment for advanced melanoma using harvested tumor cells
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
ShanghaiAges 18–75 - NCT03375983RecruitingPhase 1/Phase 2
Immune treatment with malaria cells for advanced solid cancers
This early-phase study tests a “malaria-based” immune treatment to help the immune system fight advanced cancers. It’s designed for people whose cancer can be measured on scans and whose organs and blood counts are strong enough for immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT05098171RecruitingEarly Phase 1
Study TIL cell therapy for advanced gynecologic cancers
This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05223608Recruiting
Study of people starting immunotherapy for solid tumors
This study follows people who are starting their first immune “checkpoint” treatment for a solid cancer. It collects clinic information and lab results to understand how patients respond and what factors matter most.
Lille, Hauts-de-FranceAges 18 years+ - NCT04524871RecruitingPhase 1/Phase 2
Immunotherapy combinations for advanced liver cancer
This Phase 1/2 study tests new combinations of immune system medicines in people with advanced liver cancer that cannot be cured by surgery. It looks for safer treatment and signs that the medicines can shrink or control the cancer.
Costa Mesa, CaliforniaAges 18 years+ - NCT03000244Recruiting
Long-term follow-up after stem cell or gene therapy
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
Bethesda, MarylandAges 4–120 - NCT03474822RecruitingPhase 1/Phase 2
Plasmodium immune treatment for breast and liver cancers
This early-phase study tests an immune-based treatment (using Plasmodium) for people with advanced breast cancer or advanced liver cancer. It aims to see whether the treatment is safe and whether it can help the body’s immune system fight the cancer.
Guangzhou, GuangdongAges 18–70 - NCT04724928RecruitingPhase 2
PET-CT scan to guide bladder cancer treatment decisions
This Phase 2 study checks whether an FDG PET-CT scan can help doctors better predict bladder cancer risk and adjust treatment. You may still get standard bladder cancer care, but the study uses the scan results to help decide how aggressive treatment should be.
GhentAges 18 years+ - NCT03692429RecruitingPhase 1
Testing new immune cells plus chemo for advanced colon cancer
This Phase 1 study tests CYAD-101, an immune-cell treatment made from donor T-cells, given with standard chemotherapy. It is for people with colon or rectal cancer that has spread and has not responded to prior treatments.
Tampa, FloridaAges 18 years+ - NCT07147101Recruiting
Immunotherapy for advanced liver cancer: a study on effectiveness and immune response
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06829355RecruitingPhase 2
Thymalfasin plus triple therapy for advanced colorectal cancer
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Beijing, ChinaAges 18–75 - NCT06230471RecruitingPhase 2
Pembrolizumab plus lenvatinib or chemo for advanced bile duct cancer
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
Beijing, Beijing MunicipalityAges 18–80 - NCT06353854Recruiting
Study of biomarkers in MSI-high colorectal cancer patients on immunotherapy
This trial is studying people with a specific type of advanced colorectal cancer (MSI-high/dMMR) who are starting immunotherapy with pembrolizumab. The goal is to find out which markers in the tumor might predict whether the treatment works well.
BayonneAges 18 years+ - NCT06434480Recruiting
SBRT for liver cancer with limited growth on first immunotherapy
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
Hong KongAges 18 years+ - NCT07524452RecruitingPhase 3
Becotatug vedotin plus immunotherapy for head and neck cancer
This trial tests a new combination of two drugs—becotatug vedotin (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—given before surgery to treat advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve surgical outcomes for patients with specific cancer markers.
Zhuhai, GuangdongAges 18–75 - NCT06716619RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This trial tests a new immune cell treatment made from your own lymph nodes for advanced solid tumors that haven't responded to standard therapies or have no good treatment options. It aims to see if this personalized cell therapy is safe and can help shrink tumors.
Guangzhou, GaungdongAges 18–75 - NCT07537348RecruitingPhase 2
Leucine-restricted diet with chemotherapy for advanced stomach cancer
This study tests whether a special diet low in leucine (an amino acid) combined with chemotherapy and immunotherapy can safely treat advanced stomach cancer that has spread. Researchers want to see if this dietary approach helps the treatment work better and reduces side effects.
Jinan, ShandongAges 18–70 - NCT07644039RecruitingPhase 1/Phase 2
PM54 plus immunotherapy for advanced cancer
This study tests a new drug called PM54 combined with pembrolizumab (an immunotherapy) in people with advanced cancers that have gotten worse despite prior treatment. The goal is to see if this combination can slow or stop cancer growth.
New York, New YorkAges 18 years+ - NCT07213557RecruitingPhase 2
Simvastatin with immunotherapy for ARID1A-mutated stomach cancer
This trial tests whether adding the cholesterol drug simvastatin to standard immunotherapy and chemotherapy can help people with a specific type of gastroesophageal cancer (ARID1A mutated, HER2 negative). It is for patients who have not had prior treatment for advanced disease.
Naples, ItaliaAges 18 years+
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 774 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.